Sponsors
ITOC13 thankfully acknowledges the support of the following companies and institutions
(listing in alphabetical order)
Daiichi Sankyo is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit www.daiichisankyo.com.
EUR 4.870,-
Gilead and Kite Oncology are creating the future of oncology. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our R&D programs and partnerships are creating possibilities for people with overlooked, underserved and difficult -to-treat cancers. We are focused on helping to bring more life to people with cancer and changing the way cancer is treated.
EUR 3.500,-
The ibidi portfolio comprises a broad range of slides for high-resolution cell microscopy, along with specialized assays for studying cell migration, performing 3D cell culture, and cultivating cells under flow conditions.
Precise microfluidic systems and compact, resource-saving stage top incubation systems enable realistic simulation of both static and dynamic physiological conditions. Luci, the new ibidi Micro Illumination System, brings light-induced microfabrication into every lab.
EUR 3.800,-
ImmuneWatch is a Belgium-based immunoinformatics company specialized in decoding the antigen specificity of T-cell receptors (TCRs). The TCR repertoire holds huge amounts of information on past, present and future immune responses. We leverage proprietary machine learning and databases to translate complex TCR repertoire sequencing data into actionable biological insights. Our benchmark-winning platform ImmuneWatch DETECT monitors T cell responses following vaccination or immunotherapy, and supports the identification of TCR biomarkers, characterisation of T cell products, and discovery of immunogenic antigens.
EUR 2.000,-
.jpg)
ImmuneWatch is a Belgium-based immunoinformatics company specialized in decoding the antigen specificity of T-cell receptors (TCRs). The TCR repertoire holds huge amounts of information on past, present and future immune responses. We leverage proprietary machine learning and databases to translate complex TCR repertoire sequencing data into actionable biological insights. Our benchmark-winning platform ImmuneWatch DETECT monitors T cell responses following vaccination or immunotherapy, and supports the identification of TCR biomarkers, characterisation of T cell products, and discovery of immunogenic antigens.
EUR 2.000,-
ImmuneWatch is a Belgium-based immunoinformatics company specialized in decoding the antigen specificity of T-cell receptors (TCRs). The TCR repertoire holds huge amounts of information on past, present and future immune responses. We leverage proprietary machine learning and databases to translate complex TCR repertoire sequencing data into actionable biological insights. Our benchmark-winning platform ImmuneWatch DETECT monitors T cell responses following vaccination or immunotherapy, and supports the identification of TCR biomarkers, characterisation of T cell products, and discovery of immunogenic antigens.
EUR 2.000,-
MaxCyte® empowers innovative cell and gene therapy development and drug discovery through ExPERT™ Flow Electroporation® and SeQure™ genotoxicity assays. Supported by expert scientific and regulatory guidance for 25+ years, MaxCyte has advanced safe, effective treatments that are shaping the future of medicines. Learn more at www.maxcyte.com.
EUR 9.500,-
Sanofi is an R&D-driven, AI-powered biopharma company committed to improving lives and delivering growth. We leverage our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions worldwide. Our innovative pipeline could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives and drive positive impact for our communities by addressing urgent healthcare, environmental, and societal challenges.
EUR 2.500,-
EUR 3.800,-
The purpose of the Wolfgang Wilmanns Foundation is the support of leukaemia and tumour research at the universities in Munich with the involvement of the TZM. This purpose is particularly fulfilled through awarding prizes to young researchers or research groups at the universities in Munich for outstanding performance in this area. The foundation is a non-profit organisation. Click to read more.
EUR 1.000,-
We herewith confirm that all sponsorship income is free of any attempt to influence the programme, individual sessions, subjects for discussions, content or choice of faculty members